newsfilter
← Latest News
GlobeNewswire·

Immuron Letter to Shareholders – Projects Update

Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical